Patent: 10,071,992
✉ Email this page to a colleague
Summary for Patent: 10,071,992
Title: | Diacylglycerol acyl transferase 2 inhibitors |
Abstract: | Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein. |
Inventor(s): | Boehm; Markus (Mansfield, MA), Cabral; Shawn (Groton, CT), Dowling; Matthew S. (Old Lyme, CT), Futatsugi; Kentaro (Quincy, MA), Huard; Kim (Medford, MA), Lee; Esther Cheng Yin (Brookline, MA), Londregan; Allyn T. (Barrington, RI), Polivkova; Jana (Mystic, CT), Price; David A. (Concord, MA), Li; Qifang (Stonington, CT) |
Assignee: | Pfizer Inc. (New York, NY) |
Application Number: | 15/674,914 |
Patent Claims: | see list of patent claims |
Details for Patent 10,071,992
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Glaxosmithkline Llc | TANZEUM | albiglutide | For Injection | 125431 | 04/15/2014 | ⤷ Try a Trial | 2039-02-26 |
Eli Lilly And Company | TRULICITY | dulaglutide | Injection | 125469 | 09/18/2014 | ⤷ Try a Trial | 2039-02-26 |
Eli Lilly And Company | TRULICITY | dulaglutide | Injection | 125469 | 09/04/2020 | ⤷ Try a Trial | 2039-02-26 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |